Emergent BioSolutions Secures $17 Million Contract for Smallpox Antiviral TEMBEXA® Oral Suspension

Reuters
09/15
Emergent BioSolutions Secures $17 Million Contract for Smallpox Antiviral TEMBEXA® Oral Suspension

Emergent BioSolutions Inc. has secured a $17 million contract modification to supply TEMBEXA® (brincidofovir) oral suspension, a smallpox antiviral, through the Biomedical Advanced Research and Development Authority (BARDA). This contract is part of an ongoing 10-year agreement with the U.S. Department of Health and Human Services $(HHS)$, aimed at strengthening the U.S. supply chain for critical health countermeasures. The contract follows FDA approval for the scale-up of manufacturing this formulation, which is particularly beneficial for patients who face difficulties swallowing due to age or health conditions. Emergent's collaboration with BARDA underscores the importance of maintaining a steady supply of medical countermeasures to protect vulnerable populations in the event of a smallpox outbreak.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9528998-en) on September 15, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10